Disease Modelling and Drug Discovery in Neurological Disorders

Video   Apr 29, 2016

 


About the Speaker
Zameel Cader Is Scientific Director of IMI StemBANCC and is the Director of the Oxford Headache Centre. He is also Clinical Director for Mental Health, Dementia and Neurology for the Strategic Clinical Network. He is Associate Professor in Clinical Neurosciences at the Nuffield Department of Clinical Neuroscience and the Weatherall Institute of Molecular Medicine. His research programme is focused on understanding the disease process in neurodysfunctional disorders such as migraine and neurodegenerative disorders such as Alzheimer's Disease using cell biology, model organism and human imaging studies. His group is now working with MRC Technology to bring more effective treatments arising from these findings to clinic.
AbstractThis presentation will focus on stemBANCC and its progress in developing disease relevant models as well as how we hope to turn these into drug screening assays.

 
 
 
 

Recommended Videos

Blood, Rats and Anticoagulants: The Story of Warfarin

Video

The history of warfarin, one of the earliest anticoagulant drugs, is littered with the bodies of sick cows and poisoned rats. This animation tells the story of how a bloody beginning gave rise to a life-saving medication.

WATCH NOW

Introduction to Peptides and Proteins for Bioanalysis Using LC-MS

Video

Khalid Khan, Senior Manager Business Development, discusses the basic structure of amino acids, peptides, and proteins, including specific examples like monoclonal antibodies. The ionization and fragmentation of peptides and how they differ from small molecules is also discussed.

WATCH NOW

Solutions for High-Throughput and Phenotypic Screening

Video

Accelerate drug discovery workflows with state-of-the art imaging and detection instruments, assay technologies, reagents, versatile automation systems, and powerful informatics solutions that work together to ensure consistent, accurate, physiologically relevant results. Wrest more meaning from your findings with PerkinElmer's one-of-a-kind analytics, and amplify your phenotypic or target-based screens to identify hits and lead compounds in small and focused or high-throughput volumes.

WATCH NOW

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE